4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a note issued to investors on Thursday,Weiss Ratings reports.
Several other equities research analysts have also issued reports on FDMT. Chardan Capital reissued a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a report on Tuesday. The Goldman Sachs Group decreased their target price on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Barclays dropped their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Finally, Roth Capital decreased their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.40.
Read Our Latest Analysis on 4D Molecular Therapeutics
4D Molecular Therapeutics Stock Up 6.4%
4D Molecular Therapeutics stock opened at $7.10 on Thursday. The business has a 50 day moving average price of $4.62 and a two-hundred day moving average price of $4.13. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $17.41. The stock has a market cap of $331.57 million, a price-to-earnings ratio of -2.01 and a beta of 2.83.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. On average, analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.
Institutional Trading of 4D Molecular Therapeutics
Several hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics in the 1st quarter worth approximately $39,000. Y Intercept Hong Kong Ltd bought a new stake in shares of 4D Molecular Therapeutics during the first quarter worth $41,000. Los Angeles Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the second quarter valued at $42,000. Quadrature Capital Ltd bought a new position in shares of 4D Molecular Therapeutics in the second quarter valued at about $42,000. Finally, AQR Capital Management LLC acquired a new position in 4D Molecular Therapeutics during the 1st quarter worth about $46,000. Institutional investors and hedge funds own 99.27% of the company's stock.
4D Molecular Therapeutics Company Profile
(
Get Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access